Vir Biotechnology, Inc.
VIR • NASDAQ
Vir Biotechnology, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Marianne De Backer, with a market cap of $1.3B.
CEOMarianne De Backer
Next Earnings
Upcoming earnings announcement for Vir Biotechnology, Inc.
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.28
Revenue Estimate
$135.8M
Earnings History
Past 12 earnings reports for Vir Biotechnology, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | -$0.31Est: -$0.47 | +34.0% | $64.1MEst: $19.4M | +230.1% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$1.17Est: -$0.80 | -46.2% | $240.0KEst: $4.0M | -94.0% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.80Est: -$0.72 | -11.1% | $1.2MEst: $4.7M | -74.1% | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.88Est: -$0.84 | -4.8% | $3.0MEst: $8.6M | -64.7% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$0.76Est: -$0.87 | +12.6% | $12.4MEst: $8.1M | +52.0% | 10-K |
| Oct 31, 2024 | Q3 2024 | -$1.56Est: -$1.05 | -48.6% | $2.4MEst: $5.5M | -56.8% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$1.02Est: -$0.89 | -14.6% | $3.1MEst: $7.5M | -59.0% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.48Est: -$1.05 | +54.3% | $56.4M | — | 10-Q |
| Feb 22, 2024 | Q4 2023 | -$0.86Est: -$1.01 | +14.9% | $16.8MEst: $12.2M | +38.2% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$1.22Est: -$1.21 | -0.8% | $2.6MEst: $10.2M | -74.2% | — |
| Aug 3, 2023 | Q2 2023 | -$1.45Est: -$1.20 | -20.8% | $3.8MEst: $25.9M | -85.3% | 10-Q |
| May 4, 2023 | Q1 2023 | -$1.06Est: -$0.87 | -21.8% | $63.0MEst: $51.5M | +22.2% | — |